Evidence map›Paper›PMID 38545782›Full record

ReviewArteriosclerosis, thrombosis, and vascular biology2024

Lipoprotein Particles in Cerebrospinal Fluid.

Maki Tsujita, John T Melchior, Shinji Yokoyama

Open access · greenAbstract readReview
In one paragraph

Review in Arteriosclerosis, thrombosis, and vascular biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Apolipoprotein A (ApoA) in Neurological Disorders: Connections and Insights.International journal of molecular sciences · 2025
    Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Maki Tsujita *Department of Biochemistry, Nagoya City University Graduate School of Medical Sciences, Japan (M.T.).ORCID 0000-0003-1108-621X
John T Melchior *Biological Sciences Division, Pacific Northwest National Laboratory, Richland, Washington (J.T.M.).ORCID 0000-0003-3781-2566
Shinji Yokoyama *Department of Food and Nutritional Sciences, Chubu University, Kasugai, Japan (S.Y.).
Chubu University · JPNagoya City University · JPPacific Northwest National Laboratory · US

Funding

The impact of brain lipoprotein structure and composition on amyloid beta metabolism and Alzheimer's diseaseR01NS125591 · NINDS · BATTELLE PACIFIC NORTHWEST LABORATORIES · PI John Melchior · 2024 to 2026
$2.2M
Impact of apolipoprotein E isoforms on brain lipoproteinsR03AG070480 · NIA · BATTELLE PACIFIC NORTHWEST LABORATORIES · PI MELCHIOR, JOHN · 2021 to 2022
$387k
NIA NIH HHS R03 AG070480NINDS NIH HHS R01 NS125591
6 · The paper itself

Abstract

The brain is the most lipid-rich organ in the body, and the intricate interplay between lipid metabolism and pathologies associated with neurodegenerative disorders is being increasingly recognized. The brain is bathed in cerebrospinal fluid (CSF), which, like plasma, contains lipid-protein complexes called lipoproteins that are responsible for extracellular lipid transport. Multiple CSF lipoprotein populations exist, some of which are produced de novo in the central nervous system and others that appear to be generated from protein constituents that are produced in the periphery. These CSF lipoproteins are thought to play key roles in maintaining lipid homeostasis in the central nervous system, while little else is known due to their limited accessibility and their low abundance in CSF. Recent work has provided new insights into the compositional complexity of CSF lipoprotein families and their metabolism in cerebral circulation. The purpose of this review is to summarize our current state of knowledge on the composition, origin, and metabolism of CSF lipoproteins.

Indexed as

LipoproteinsAnimalsBrainHumansLipid MetabolismNeurodegenerative DiseasesLipoproteinsapolipoproteinscentral nervous systemcerebrovascular circulationlipid metabolismlipoproteinsneurodegenerative diseases

Identifiers

PMID38545782
PMCPMC11342562
OpenAlexW4393265870

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.